Alterity Therapeutics Files 6-K, Presents ATH434 Data
Ticker: PRNAF · Form: 6-K · Filed: Apr 29, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-data, filing-update, clinical-trial
Related Tickers: ATHE
TL;DR
ALTERITY THERAPEUTICS (ATHE) filed a 6-K on 4/29, presenting new data on their drug ATH434. Check filings for details.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on April 29, 2024, to report on new data presented for their drug candidate ATH434. This filing incorporates information into existing registration statements on Form S-8 and Form F-3.
Why It Matters
This filing signals ongoing development and data presentation for ATH434, a key drug candidate for Alterity Therapeutics, potentially impacting investor sentiment and future clinical trial progress.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the underlying drug development and data presentation carry inherent risks associated with clinical trials and regulatory approvals.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH434 (drug_candidate) — Drug candidate presented in the filing
- April 29, 2024 (date) — Filing date
- Form S-8 (filing) — Incorporated by reference
- Form F-3 (filing) — Incorporated by reference
FAQ
What specific new data was presented regarding ATH434?
The filing indicates that Exhibit 99.1 contains 'Alterity Presents New Data on ATH434', but the specific details of this data are not included in the provided text of the 6-K itself.
What is the purpose of incorporating this 6-K into existing registration statements?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3, likely to update or supplement information related to securities offerings or ongoing reporting requirements.
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Yes, Alterity Therapeutics indicates it files annual reports under Form 20-F.
What was Alterity Therapeutics' former company name?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-04-29 06:13:38
Filing Documents
- ea0204854-6k_alterity.htm (6-K) — 14KB
- ea020485401ex99-1_alterity.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-036798.txt ( ) — 37KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Presents New Data on ATH434 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: April 29 , 2024 2